Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI

Aim/hypothesisType 2 diabetes increases the risk not only of vascular dementia but also of Alzheimer’s disease. The question remains whether diabetes increases the risk of Alzheimer’s disease by diabetic vasculopathy or whether diabetes influences directly the development of Alzheimer neuropathology. In vivo, hippocampal and amygdalar atrophy on brain MRI are good, early markers of the degree of Alzheimer neuropathology. We investigated the association between diabetes mellitus, insulin resistance and the degree of hippocampal and amygdalar atrophy on magnetic resonance imaging (MRI) accounting for vascular pathology.MethodsData was obtained in a population-based study of elderly subjects without dementia between 60 to 90 years of age. The presence of diabetes mellitus and, in non-diabetic subjects, insulin resistance was assessed for 506 participants in whom hippocampal and amygdalar volumes on MRI were measured. We assessed the degree of vascular morbidity by rating carotid atherosclerosis, and brain white matter lesions and infarcts on MRI.ResultsSubjects with diabetes mellitus had more hippocampal and amygdalar atrophy on MRI compared to subjects without diabetes mellitus. Furthermore, increasing insulin resistance was associated with more amygdalar atrophy on MRI. The associations were not due to vascular morbidity being more pronounced in persons with diabetes mellitus.Conclusions/interpretationType 2 diabetes is associated with hippocampal and amygdalar atrophy, regardless of vascular pathology. This could suggest that Type 2 diabetes directly influences the development of Alzheimer neuropathology.

[1]  R. Bucala,et al.  Advanced glycation end products contribute to amyloidosis in Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[2]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. , 1997, JAMA.

[3]  T. Harris,et al.  Longitudinal association of vascular and Alzheimer’s dementias, diabetes, and glucose tolerance , 1999, Neurology.

[4]  A. Convit,et al.  Reduced glucose tolerance is associated with poor memory performance and hippocampal atrophy among normal elderly , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Rockwood,et al.  Diabetes mellitus and the Risk of Dementia, Alzheimer’s Disease and Vascular Cognitive Impairment in the Canadian Study of Health and Aging , 2002, Dementia and Geriatric Cognitive Disorders.

[6]  S. Lovestone,et al.  Genetic variability in the insulin signalling pathway may contribute to the risk of late onset Alzheimer's disease , 2002, Journal of neurology, neurosurgery, and psychiatry.

[7]  Matthijs Oudkerk,et al.  Incidence and Risk Factors of Silent Brain Infarcts in the Population-Based Rotterdam Scan Study , 2003, Stroke.

[8]  J. Haines,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. , 1997, JAMA.

[9]  Gene E. Alexander,et al.  Volumes of Medial Temporal Lobe Structures in Patients with Alzheimer’s Disease and Mild Cognitive Impairment (and in Healthy Controls) , 1998, Biological Psychiatry.

[10]  C. Brayne,et al.  Vascular Risks and Incident Dementia: Results from a Cohort Study of the Very Old , 1998, Dementia and Geriatric Cognitive Disorders.

[11]  P. Tariot,et al.  Diabetes and Dementia in Long‐Term Care , 1999, Journal of the American Geriatrics Society.

[12]  M. Breteler.  Vascular Involvement in Cognitive Decline and Dementia: Epidemiologic Evidence from the Rotterdam Study and the Rotterdam Scan Study , 2000, Annals of the New York Academy of Sciences.

[13]  W. Markesbery,et al.  Hippocampal volume as an index of Alzheimer neuropathology: Findings from the Nun Study , 2002, Neurology.

[14]  Margaret A. Pericak-Vance,et al.  Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease , 1997 .

[15]  Tom den Heijer,et al.  Hippocampal Head Size Associated with Verbal Memory Performance in Nondemented Elderly , 2002, NeuroImage.

[16]  C. Jack,et al.  Memory and MRI-based hippocampal volumes in aging and AD , 2000, Neurology.

[17]  A. Hofman,et al.  Cerebral white matter lesions and cognitive function: The Rotterdam scan study , 2000, Annals of neurology.

[18]  J. Heitner,et al.  Diabetics do not have increased Alzheimer-type pathology compared with age-matched control subjects , 1997, Neurology.

[19]  L. Frölich,et al.  A Disturbance in the Neuronal Insulin Receptor Signal Transduction in Sporadic Alzheimer's Disease , 1999, Annals of the New York Academy of Sciences.

[20]  L. Launer,et al.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.

[21]  M. Bobinski,et al.  The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease , 1999, Neuroscience.

[22]  A. Hofman,et al.  Non-insulin-dependent Diabetes Mellitus (niddm) Association of Diabetes Mellitus and Dementia: the Rotterdam Study , 2022 .

[23]  Arno W. Hoes,et al.  Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. , 1997, Circulation.

[24]  M. Laakso,et al.  How good a marker is insulin level for insulin resistance? , 1993, American journal of epidemiology.

[25]  G. Schellenberg,et al.  Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease , 1998, Neurology.

[26]  A Hofman,et al.  Diabetes mellitus and the risk of dementia , 1999, Neurology.

[27]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[28]  C. Jack,et al.  Prediction of AD with MRI-based hippocampal volume in mild cognitive impairment , 1999, Neurology.

[29]  S. Black,et al.  Beyond the hippocampus , 2001, Neurology.

[30]  W. Markesbery,et al.  Brain infarction and the clinical expression of Alzheimer disease. , 1997, JAMA.

[31]  J. Ávila,et al.  Analysis of microtubule-associated protein tau glycation in paired helical filaments. , 1994, The Journal of biological chemistry.

[32]  H. Valkenburg,et al.  Prevalence and Determinants of Glucose Intolerance in a Dutch Caucasian Population: The Hoorn Study , 1995, Diabetes Care.

[33]  James A. Mortimer,et al.  Brain Infarction and the Clinical Expression of Alzheimer Disease-Reply , 1997 .

[34]  K. Jellinger,et al.  Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease , 1998, Journal of Neural Transmission.

[35]  F. Boller,et al.  Specificity of temporal amygdala atrophy in Alzheimer's disease: quantitative assessment with magnetic resonance imaging. , 1996, Dementia.

[36]  D. Alkon,et al.  Role of insulin and insulin receptor in learning and memory , 2001, Molecular and Cellular Endocrinology.

[37]  Nick C Fox,et al.  Assessing the onset of structural change in familial Alzheimer's disease , 2003, Annals of neurology.

[38]  A Hofman,et al.  A follow‐up study of blood pressure and cerebral white matter lesions , 1999, Annals of neurology.

[39]  Matthew P. Frosch,et al.  Insulin-degrading enzyme regulates the levels of insulin, amyloid β-protein, and the β-amyloid precursor protein intracellular domain in vivo , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[40]  E G Tangalos,et al.  Memory function in very early Alzheimer's disease , 1994, Neurology.

[41]  Johanna Kuusisto,et al.  Association between features of the insulin resistance syndrome and alzheimer's disease independently of apolipoprotein e4 phenotype: cross sectional population based study , 1997, BMJ.

[42]  P. O'Brien,et al.  Risk of dementia among persons with diabetes mellitus: a population-based cohort study. , 1997, American journal of epidemiology.

[43]  A. Hofman,et al.  Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: the Rotterdam Study. , 1998, Archives of neurology.

[44]  T. Pagano,et al.  Insulin receptors and insulin action in the brain: review and clinical implications , 2000, Neuroscience & Biobehavioral Reviews.

[45]  A. Convit,et al.  Specific Hippocampal Volume Reductions in Individuals at Risk for Alzheimer’s Disease , 1997, Neurobiology of Aging.

[46]  J. Haines,et al.  Effects of Age, Sex, and Ethnicity on the Association Between Apolipoprotein E Genotype and Alzheimer Disease: A Meta-analysis , 1997 .

[47]  P. Greengard,et al.  Does insulin dysfunction play a role in Alzheimer's disease? , 2002, Trends in pharmacological sciences.

[48]  P A Wolf,et al.  Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. , 2001, Circulation.

[49]  A. Hofman,et al.  Determinants of disease and disability in the elderly: The Rotterdam elderly study , 1991, European Journal of Epidemiology.

[50]  I. Kurochkin.  Insulin-degrading enzyme: embarking on amyloid destruction. , 2001, Trends in biochemical sciences.

[51]  P. Riederer,et al.  Alzheimer's disease – synergistic effects of glucose deficit, oxidative stress and advanced glycation endproducts , 1998, Journal of Neural Transmission.

[52]  J. Lindsay,et al.  Vascular dementia : incidence and risk factors in the Canadian study of health and aging. , 2000, Stroke.

[53]  R. Mayeux,et al.  Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. , 2001, American journal of epidemiology.

[54]  Hiromitsu Iwamoto,et al.  Incidence and risk factors of vascular dementia and Alzheimer's disease in a defined elderly Japanese population , 1995, Neurology.